drugset / Trial / NCT01266369
Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective is to compare efficacy and safety of AB1010 at 3 or 6 mg/kg/day in treatment of patients with mastocytosis with handicap and bearing activating point mutations in the phosphotransferase domain of c-Kit such as the main mutation Asp-816-Val (D816V).
Timeline
- Start
- 2007-02
- Primary completion
- 2007-11
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Masitinib | Small molecule | 3 mg/kg | — |
| Subject | Masitinib | Small molecule | 6 mg/kg | — |